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It is now over 200 years since the British surgeon John Hunter first
used the term angiogenesis to describe the growth of new blood
vessels in the developing reindeer antler (Hunter, 1787) and some
30 years since the possibility of antagonizing angiogenesis as a
novel anticancer strategy first became recognized by the scientific
community. It is only in the last 5 years, however, that the field of
(anti)angiogenesis research has undergone an explosive growth
in activity (Figure 1). A primary reason for this has been an
increasing optimism amongst researchers that anti-angiogenesis
does indeed, at the present time, represent one of the most exciting
opportunities for the development of completely new approaches
to the treatment of cancer. The purpose of this commentary is to
give an assessment of where we stand at present and of the future
potential for angiogenic inhibitors in cancer therapy.
CURRENT STATUS OF LEADING ANGIOGENESIS
INHIBITORS
At least 30 angiogenesis inhibitors are currently being assessed
in clinical trials. Most are in clinical phase I or II studies. A few,
however, have progressed to phase III evaluation, potentially
leading to Federal Drug Administration (FDA) approval (Table 1).
Leading anti-angiogenic targets that have been identified are (1)
the inhibition of matrix metalloproteinases, (2) antagonism of the
VEGF pathway of angiogenic induction, and (3) inhibition of the
avb3-integrin–vitronectin interaction that is pivotal in mediating
endothelial cell adhesion to the extracellular matrix during neo-
vascularization.
Some of the most advanced angiogenesis inhibitors currently
being evaluated in clinical trials are matrix metalloproteinase
(MMP) inhibitors. Marimastat (British Biotech, Annapolis, MD,
USA) was the first MMP inhibitor to be involved in rigorous
clinical trials. In a phase III study incorporating 400 patients with
advanced pancreatic cancer, marimastat showed no single therapy
benefit over gemcitabine, the ‘drug of choice’. Nevertheless, mari-
mastat at 25 mg twice a day was as effective as gemcitabine and
appeared to have an improved therapeutic index at lower doses 
(5 mg or 10 mg) with fewer side-effects. It is clear that further
studies of marimastat will be needed before a complete assessment
of the efficacy, tolerability and dose regimen can be made. To this
end, nine randomized controlled studies of marimastat in a range
of solid tumours (pancreatic, non-small-cell lung, breast cancers)
are ongoing and the current expectation is that these data will be
available within the next 3 years.
Other metalloproteinase inhibitors in advanced trials are Bay
12-9566 (Bayer, West Haven, CT, USA) and Ag3340 (Agouron,
La Jolla, CA, USA). Several international phase III clinical trials
using Bay 12-9566 against solid tumours including lung, ovarian
and pancreatic cancer are being conducted. In addition, the
National Cancer Institute (NCI) is currently performing phase I
studies designed to evaluate a possible use of Bay 12-9566 in
combination regimens with doxorubicin, fluorouracil or low-dose
leucovorin. There are several phase III clinical trials underway to
evaluate AG3340 alone or in combination with the anticancer
drugs paclitaxel/carboplatin for the treatment of non-small-cell
lung cancer and mitoxantrone/prednisone for hormone-refractory
prostate cancer. It has been shown that the anti-tumour efficacy of
AG3340 is associated with maintenance of a minimum plasma
concentration but not total daily dose, exposure or peak plasma
concentrations (Brekken et al, 1999).
Attempts to abrogate the angiogenic activity of vascular
endothelial growth factor (VEGF) have varied from inactivation of
VEGF itself by using, for example, antibodies (Mordenti et al,
1999) or soluble receptors to specific inhibition of the VEGF
receptor tyrosine kinase (Lin et al, 1998). The latter includes
ZD4190, an anilino quinazoline derivative that specifically
inhibits the VEGF receptor 2 (KDR) tyrosine kinase and has
shown widespread anti-tumour activity in in vivo animal models
following oral administration (Hennequin et al, 1999; Ogilvie
et al, 1999). Another VEGF receptor tyrosine kinase inhibitor
showing much promise is SU5416 (Sugen Inc., CA, USA).
The interaction of the angiogenic endothelial cell with extra-
cellular vitronectin mediated via the av integrin is crucial during
angiogenesis. It follows that antibodies to the avb3 integrin are
strongly anti-angiogenic and mouse monoclonals have been
humanized as ‘Vitaxin’ to permit clinical trials. Preliminary results
have shown stable disease or shrinkage in eight of 14 late-stage
cancer patients. No side-effects have been observed so far (Eliceiri
and Cheresh, 1999).
ANGIOSTATIN AND ENDOSTATIN, EMERGING
ANGIOGENESIS INHIBITORS
An area of intense current interest is that of potent naturally occur-
ring inhibitors of angiogenesis being encrypted within larger
molecules with no angiogenic activity but having other functions.
Proteolytic cleavage releases the active material. Such molecules
include angiostatin, a fragment of plasminogen (O’Reilly et al,
1997); endostatin, a fragment of collagen type 18 (O’Reilly et al,
1997); a 16 kDa fragment of prolactin; and a fragment of throm-
bospondin. Attention has been most focused on endostatin, which
is able to bring about successive waves of substantial tumour
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tance (Boehm et al, 1997).
One year ago, a front page article in the New York Times
(Kolata, 1998) initiated speculation that cancer could be treated
with angiostatin and endostatin. That article, and coverage by
other media, generated intense public interest in angiogenesis
inhibitors and a subsequent controversial and emotional debate
(Wadman, 1998; Cohen, 1999; Harris, 1999; Rowe, 1999). The
controversy was fueled as studies on endostatin in laboratories
outside Boston were unable to confirm the endostatin results,
showing only a slight growth retardation of Lewis lung carcinoma
(a difficult tumour to treat with chemotherapeutic agents) in mice.
Members of the NCI went to Folkman’s laboratory in Boston to
clarify why the results differed from those in the original study. In
Boston, subsequent results were consistent with previous experi-
ments, showing striking inhibition of tumour growth. Variations in
experimental techniques between the two laboratories, such as
injecting mice, as well as storage, handling and purification of
endostatin, are assumed to have been responsible for the previ-
ously observed lack of agreement in results.
The NCI’s success with mouse endostatin – just a few months
after it had been announced publicity that it could not replicate the
results – allowed the Institute to initiate plans for the testing of
human endostatin in patients, pending full-scale toxicology studies.
In early fall of 1999 two sites were expected to conduct phase I
studies with approximately 15–25 patients each in patients with
solid tumours, including lung, breast, colon and prostate carcinoma.
To launch clinical studies it has been necessary to scale up the
production of endostatin. By applying a yeast expression system it is
now possible to produce soluble human endostatin at quantities
sufficient for clinical assessment in man (Sim et al, 1999).
Animal studies with angiostatin and endostatin have so far been
only with transplanted tumours, which show a different biology
when compared to organ-specific, spontaneous tumours and are
not necessarily accurate predictors of what will happen in natural
human cancers. Thus, a transgenic mouse model of pancreatic islet
carcinogenesis (RIP1-Tag2) was used as a model to examine the
effect of several angiogenesis inhibitors on multistage tumorigen-
esis (Bergers et al, 1999). Apart from endostatin, angiostatin and a
combination of both, AGM-1470 (TNP470; a fumagillin deriva-
tive which is thought to inhibit endothelial cell proliferation by
irreversible binding to the enzyme methionylaminopeptidase-2)
(Sin et al, 1997) and BB-94 (batimastat; a matrix metallopro-
teinases inhibitor) (Talbot and Brown, 1996) were tested for their
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Figure 1 Publications in angiogenesis and anti-angiogenesis between 1990 and 1998anti-angiogenic potency in a prevention, intervention and regres-
sion trial in the RIP-Tag mice. The four angiogenesis inhibitors
examined showed distinct efficacy profiles varying from about
60% to 85% depending on the stage of carcinogenesis being
targeted. However, none of the agents tested completely prevented
the angiogenic switch, blocked the growth of small tumours, or
fully resolved lethal tumour burden. These results suggest that the
prevention and treatment of human spontaneous organ-specific
malignancies with anti-angiogenic agents is going to be more
complex and difficult than was originally anticipated. For
example, it is not possible to predict if human tumours are going to
respond in vivo to human endostatin as do mouse tumours to
mouse endostatin.
The story of angiostatin and endostatin shows that much has yet
to be learned about anti-angiogenic agents. Several years after the
discovery of angiostatin and endostatin, recent reports began to
give insight into the mechanism of anti-angiogenic action of those
agents. Angiostatin has been shown to inhibit matrix-enhanced
plasminogen activation, resulting in reduced invasive activity
(Stack et al, 1999). Angiostatin’s antiproliferative effect was
reported to be mediated by binding to the a/b-subunits of ATP
synthase (Moser et al, 1999). The last observation is noteworthy as
it might be possible to develop small molecules that could mimic
angiostatins effect on the ATP synthase-binding protein. Smaller
molecules would reduce the problem of immunogenicity, might be
more easy to synthesize and might be taken orally. Less is known
about the mechanism of action of endostatin but it is believed to
induce apoptosis of endothelial cells by reducing anti-apoptotic
proteins like Bcl-2 (Dhanabal et al, 1999b).
OTHER ANGIOGENESIS INHIBITORS
It may not be the agents currently in trials that work best in the
end. Several hundred angiogenesis inhibitors have been identified
and the list is mushrooming, including exotic substances like those
extracted from green tea (Cao and Cao, 1999). It is possible that
some of the newly identified agents are going to be more potent
than the currently known drugs. Although the chance of an anti-
angiogenic agent moving into standard medical practice is esti-
mated to be in the order of 1:10 000, a ‘gold-rush’ atmosphere has
developed to detect or develop such a compound as the potential
market is comparable to antibiotics and chemotherapeutics, that is
of the order of billions of dollars per year (Brem, 1998).
Some previously known drugs have also been shown to be
angiogenesis inhibitors. For example thalidomide, a drug with a
tarnished past, achieved a comeback after its antiangiogenic
properties were identified. (D’Amato, 1994), and it is almost no
surprise that aspirin with its pleiotropic effects has been identified
as an angiogenesis inhibitor (Tsujii et al., 1998).
ANTI-ANGIOGENESIS AND CONVENTIONAL
ANTICANCER THERAPIES
Many traditional cancer therapies probably have an anti-
angiogenic component. Thus, chemotherapeutic agents such as the
taxanes and camptothecins have anti-angiogenic properties that
may, at least in part, account for their efficacy as anti-tumour
agents (Belotti et al, 1996). It is possible that low-dose standard
chemotherapeutic regimens may inhibit angiogenesis without
being cytotoxic to the tumour. Anti-oestrogen therapy for the
prevention or adjuvant treatment of breast cancer may also be
mediated by affecting vascularity as tamoxifen has been shown to
inhibit angiogenesis (Van der Schaft et al, 1999).
Further evidence for the anti-angiogenic activity of conven-
tional as well as experimental cancer therapies comes from a
growing number of studies that have shown that damage of blood
vessels precede or accompanies tumour regression after radiation
therapy, hyperthermia, photodynamic therapy or administration of
a variety of biological response modifiers such as interferon,
tumour necrosis factor, interleukins or endotoxin (Baillie, 1995).
Finally, it is also known that many oncogenes modulate the expres-
sion of angiogenic factors, such as VEGF, and thus therapies
targeting these genes may also be effective through the inhibition
of angiogenesis (Rak et al, 1995).
DESIGNING CLINICAL TRIALS OF
ANGIOGENESIS INHIBITORS
There are important differences between anti-angiogenic clinical
trials and traditional trials of cytotoxics (Kerbel and Pluda, 1999).
In phase I trials most of the anti-angiogenic agents have been
exceptionally well tolerated, lacking many of the side-effects
associated with conventional cancer chemotherapies (neutropenia,
nausea and vomiting etc.). Due to this lack of measurable toxicity,
it has been difficult to define the maximum tolerated dose and to
identify a recommended drug dose. Further, in phase II studies it
has proven a challenge to assess the effectiveness of angiogenic
drugs. These relate to the observations that most of those agents
do not necessarily cause tumour shrinkage but induce tumour
dormancy leading to stable disease. Exceptions are agents used for
vascular targeting (Huang et al, 1997) and the more recently
described natural inhibitors, such as angiostatin and endostatin.
Measuring time-to-progression is a parameter to determine stable
disease but it tends to be a heterogeneous time point, with great
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Table 1 Most advanced anti-angiogenic agents in clinical trials (source: NCI
Cancer Trials – http://cancertrials.nci.nih.gov)
Drug Trial Mechanism
Marimastat Phase III against pancreas, Synthetic MMP inhibitor
non-small-cell lung, breast
cancers
Bay 12-9566 Phase III against lung, Synthetic MMP inhibitor
ovary and pancreatic
cancers
AG3340 Phase III against non-small- Synthetic MMP inhibitor
cell lung; phase III against
prostate cancer
Thalidomide Phase II against Kaposi’s Unknown
sarcoma, glioblastoma,
breast, prostate and lung
cancers
Anti-VEGF Phase II/III against lung, Monoclonal antibody to
antibody breast, prostate, colorectal VEGF
and renal cancers
SU5416 Phase I/II against Kaposi’s Blocks VEGF receptor
sarcoma, phase I/II against signalling
metastatic colorectal cancer,
and phase I/II against
advanced malignancies
CAI Phase II/III against ovarian, Inhibitor of calcium influx
non-small-cell lung, and
renal cell cancers
MMP, matrix metalloproteinase; VEGF, vascular endothelial growth factor.interpersonal variation (Kerbel and Pluda, 1999). Two methods
have, however, been usefully applied to assess responsiveness to
anti-angiogenic therapy: (i) measurement of serum levels of angio-
genic peptides and (ii) magnetic resonance imaging to detect
contrast uptake and washout in tumours. Due to the difficulties of
phase II trials, it seems likely that many anti-angiogenesis drugs
will proceed rapidly from phase I to phase III.
CONCLUSIONS
For many years the perceived role for angiogenesis inhibitors in
the clinic was either in the adjuvant situation or in combination
with conventional cytotoxic’s permitting use of lower doses of
the latter. Recently, however, the arrival of new angiogenesis
inhibitors such as endostatin that achieve substantial tumour
regression points to a potentially greater role for angiogenesis
inhibitors in oncology. Clinical application of anti-angiogenic
agents looks an increasingly realistic prospect. Clearly, the next
few years will see a period of intense research into the clinical
potential for inhibitors of angiogenesis in the treatment of cancer.
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